Article

Exploring the Placebo Response in Cancer Survivors

Author(s):

A clinical trial at the University of Alabama will be enrolling patients in the first-ever study of an open-label placebo in cancer.

A clinical trial at the University of Alabama will be enrolling patients in the first study of an open-label placebo in cancer. Cancer survivors with moderate-levels of cancer-related fatigue, who have completed treatments for at least 6 months, would be eligible to participate.

One group of participants will receive the placebo pill for 2 weeks and the second group will act as a control. The cohorts will trade places after a week-long washout period. Saliva samples from trial participants will be analyzed for potential biomarkers to identify genetic predisposition to a placebo response, if any.

The Program in Placebo Studies and the Therapeutic Encounter at Harvard University and Beth Israel Deaconess Medical Center, run by Ted Kaptchuk, has done several open-label placebo studies in patients with irritable bowel syndrome, migraine, and depression.

Read more at newswise: http://bit.ly/1Lo2wZ4

Related Videos
Dr Rebecca Haberman
Susan Escudier, MD, FACP
2 experts in this video
2 experts in this video
Dr Michael Bernstein
Screenshot of an interview with Evangelia Vlachou, MD
Screenshot of an interview with Barry Goy, MD
1 expert is featured in this series.
5 experts are featured in this series
5 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo